Athira Pharma Inc. (ATHA) Issues 2022 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Tanker struck by projectile in Strait of Hormuz
Athira Pharma Provides 2022 Pipeline Outlook
January 5, 2022 7:00 AM ESTTopline data from ACT-AD Phase 2 Alzheimers disease study in 2Q22
LIFT-AD Phase 3 Alzheimers disease study sample size increased to strengthen statistical power of co-key secondary endpoints and enhance the potential for a single pivotal clinical study
Milestones achieved with initiation of SHAPE Phase 2 Parkinsons disease dementia clinical trial and IND filing for ATH-1020
BOTHELL, Wash., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Athira Pharma,... More
